However, she can perform this merely with her arms that are bare.

Actually https://www.affordable-papers.net whenever the matter is distressing or hopeless, it really is critical to supply the reader a sense the issues could be overcome. Subject is a key facet of our own lifestyles. Story writing enables you to talk about yesteryear or future. They’re additionally experienced investigators and they realize just how to impart understanding effectively. I should stop here. To understand the meaning of learning grammar, click the link. It does not work in case your grammar isn’t that great. Use numerous phrase constructions in purchase for your essay isn’t dreary and boring.

BIO CEO sets itself apart by providing a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. This year’s conference was no exception, as it featured issue-oriented and educational sessions focused on trending therapeutic areas and key business issues, company presentations, one-on-one meetings, andnetworking opportunities. This year’s event also featured the return of the Buzz of BIO competition, which seeks to recognize the most innovative companies in the biotech sector looking to take their product to the next phase. The winners join more than 170 early and late-stage private biotech companies and emerging public companies who presented at the event.

The competition nominates companies in three categories: (1) Public Therapeutic Biotech, (2) Private Therapeutic Biotech, and (3) Diagnostics and Beyond (a new category being introduced this year). Nominations take place over a two week period, and the top ten companies in each category are named as finalists. The list of companies are presented to the public to vote, and each company with the most votes in each category wins.

OneMedNews profiled this year’s finalists and overall winners:

Buzz of BIO Winners

Public Therapeutic Biotech Winner: Agile Therapeutics, Inc (NASDAQ: AGRX) – Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Agile’s product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Their lead product candidate, Twirla (or AG200-15) is designed as a once-weekly prescription contraceptive patch that recently completed Phase 3 trials. The company also boasts a strong pipeline of other transdermal contraceptive products, such as AG200-ER,  (a regimen designed to allow a woman to extend the length of her cycle) and AG200-SP (a regimen designed to provide a shortened hormone-free interval) and AG890 (a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen). For more on Agile, visit the company’s website.

Private Therapeutic Bioetch Winner: Centrexion Therapeutics, Corp. – Centrexion is a company focused on advancing the treatment of chronic moderate to severe pain with one of the largest exclusively pain-focused pipelines of non-opioid therapies in active development. The company recognizes the needs of over a quarter of a billion patients living with chronic pain worldwide, and aims to develop new, safer and more effective therapies that overcome the limitations and challenges associated with current pain treatments. Founded by world-renowned leaders in drug development and well-funded by key investors, Centrexion is building a pain treatment powerhouse to address the substantial and growing global chronic pain epidemic. Their most advanced therapeutic, CNTX-4975, is a based on a proprietary STRATI technology that provides rapid onset, high degree and long duration of relief from localized moderate to severe pain. CNTX-4975 is currently in late-stage development for the treatment of moderate to severe pain from Morton’s neuroma and osteoarthritis. It is also in Phase 3 clinical trials for canine osteoarthritis pain in pet dogs. For more on Contrexion, visit the company’s website.

Diagnostics and Beyond Winner: Oncocyte (NYSE MKT: OCX) – OncoCyte is primarily focused on the development and commercialization of novel, non-invasive blood and urine (“liquid biopsy”) diagnostic tests for the early detection of cancer to improve health outcomes through earlier diagnoses, to reduce the cost of care through the avoidance of more costly diagnostic procedures, including invasive biopsy and cystoscopic procedures, and to improve the quality of life for cancer patients. While current biopsy tests use invasive surgical procedures to provide tissue samples in order to determine if a tumor is benign or malignant, OncoCyte is developing a next generation of diagnostic tests that will be based on liquid biopsies using blood or urine samples. OncoCyte’s pipeline products are intended to be confirmatory diagnostics for detecting lung, bladder and breast cancer. The company’s diagnostic tests are being developed using proprietary sets of genetic and protein markers that differentially express in specific types of cancer. For more on OncoCyte, visit the company’s website.

Buzz of BIO Finalists

Altimmune, Inc. – Altimmune is a clinical stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The company has two proprietary platform technologies, RespirVec and Densigen, each of which has been shown to activate the immune system in distinctly different ways than traditional vaccines. Using these technologies, Altimmune has developed three novel clinical stage product candidates that potentially represent an entirely new approach to harnessing the immune system. The most advanced product candidate, NasoVAX, is a Phase 2-ready intranasally-delivered recombinant influenza vaccine offering broad and rapid protection with potential for significant advantages over traditional flu vaccines. For more on Altimmune, visit the company’s website.

Arcturus Therapeutics – Founded in 2013 and based in San Diego, Arcturus Therapeutics, Inc. is an RNA medicines company with enabling technologies called UNA Oligomer chemistry and LUNAR nanoparticle delivery. The company’s RNA therapeutics platform can be applied toward all types of RNA medicines including small interfering RNA, messenger RNA, antisense RNA, microRNA and gene editing therapeutics. Arcturus’ proprietary UNA technology can be used to target any gene in the human genome, as well as viral genes, and other species for therapeutic purposes. The company’s involvement in the development of RNA therapeutics has led to collaborations and license agreements with Janssen Pharmaceuticals, Inc. and Ultragenyx Pharmaceutical, Inc. For more on Arcturus, visit the company’s website.

Caladrius Biosciences, Inc. (NASDAQ: CLBS) – Caladrius is advancing a proprietary platform technology for immunomodulation by pioneering the use of T regulatory cells as an innovative therapy for recent onset type 1 diabetes.  Their product candidate, CLBS03, is the subject of an ongoing Phase 2 clinical trial and has been granted Fast Track designation by the FDA. The company’s PCT subsidiary is a leading development and manufacturing partner to the cell therapy industry.  PCT works with its clients to overcome the fundamental challenges of cell therapy manufacturing by providing a wide range of innovative services including product and process development, GMP manufacturing, engineering and automation, cell and tissue processing, logistics, storage and distribution, as well as expert consulting and regulatory support. For more on Caladrius, visit the company’s website.

ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV) – ContraVir is a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies with a specific focus on developing a potentially curative therapy for hepatitis B virus. The company is developing two novel anti-HBV compounds with complementary mechanisms of action: Tenofovir Exalidex, a highly potent analog of the successful antiviral drug tenofovir currently in Phase 2a, which has demonstrated the potential for low, once a day dosing, potentially reducing renal and bone side effects; and CRV431, a next generation cyclophilin inhibitor with a unique structure that increases its potency and selective index against HBV. For more information visit the company’s website.

ProLung – ProLung’s mission is to make a difference in time for lung cancer patients. The company has established itself as a leader in innovative predictive analytics technology and non-invasive biomarkers for the risk stratification of lung cancer. ProLung develops, tests, and commercializes solutions which may shorten the time to diagnosis and expand the therapeutic window for lung cancer patients. Their predictive analytics platform for lung cancer risk stratification is approved for investigational use only in the US. Their product, the EPN Scan, uses an established bio-conductance technology – similar to an EEG or EKG, to risk stratify patients who are likely to have lung lesions suspicious for cancer. The patented computerized scan can be used in conjunction with Low-Dose CT screening to evaluate masses identified by these scans for high or low risk of malignancy.For more on ProLung, visit the company’s website.

RXi Pharmaceuticals Corporation (NASDAQ: RXII) – RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a clinical-stage company developing innovative therapeutics that address significant unmet medical needs.  Building on the pioneering discovery of RNAi, scientists at RXi Company have harnessed the naturally occurring RNAi process, which has the ability to “silence” or down-regulate the expression of a specific gene that may be overexpressed in a disease condition.  RXi developed a robust RNAi therapeutic platform, including self-delivering RNA compounds, that have the ability to highly selectively block the expression of any target in the genome, thus providing applicability to many therapeutic areas. For more on RXi, visit the company’s website.

Salarius Pharmaceuticals – Salarius Pharmaceuticals is developing targeted therapies to treat pediatric and other cancers, including prostate cancer. Their lead compound, SP-2577, is a reversible inhibitor of LSD1, an enzyme involved in abnormal epigenetic promotion of cancer. SP-2577 works by reversing a faulty genomic process that promotes cancer, allowing the company to initially target the treatment of Ewing’s sarcoma. SP-2577 represents a potential paradigm shift in the treatment of pediatric cancer and may also apply to hormonal cancers, such as prostate, breast and ovarian cancer, and perhaps other conditions like leukemia. The company is scheduled to begin clinical trials in Q1 2017 by testing patients suffering from Ewing sarcoma and castration resistant prostate cancer. For more on Salarius, visit the company’s website.

Symic Bio, Inc. –  Symic Bio is a clinical-stage biotech company developing a new category of therapeutics thatare matrix regulators. Matrix regulators target the non-cellular component of tissue and enable new ways to affect disease and healing processes with potential applications in a wide variety of indications. Symic Bio currently has two clinical candidates, SB-030 for the treatment of critical limb ischemia and SB-061 directed at disease modification in the treatment of osteoarthritis. In addition, Symic Bio is investigating applications in the areas of fibrosis, oncology and diseases of the central nervous system. For more on Symic Bio, visit the company’s website.

Universal Stabilization Technologies, Inc. – Universal Stabilization Technologies, Inc. (UST) is a service and product development company. UST will first focus on the development of ambient temperature stable platelets and erythrocytes. The company’s VitriLife service provides industrial scale preservation and needle-free delivery device formulation services for the development of thermostable biopharmaceuticals. VitriLife is an effective, scalable technology for the preservation of sensitive bacteria, viruses, biopharmaceuticals and highly sensitive small molecule pharmaceuticals at room or higher temperatures by desiccation and subsequent vitrification. Molecular mobility in the glass state is arrested, ensuring long-term stability of the preserved material, even at elevated temperatures. For more on UST and VitriLife, visit the company’s website.

SafeHeal seeks to be a global leader in digestive anastomosis protection devices and projects revenue to hit €10 million by 2020 and €100 million in 2025.

www.onemednews.com

Catalia Health, a San Francisco-based company, is garnering attention from the medtech industry with its healthcare robot. The “Mabu” is a personal healthcare companion aimed at providing assistance to patients suffering from chronic disease, while also collecting data for use by healthcare professionals. Mabu uses a cloud-based platform to allow patients to address their healthcare issues effectively and timely via a mobile or web messaging system.

With hundreds of millions of people around the globe suffering from non-communicable diseases, Catalia has a unique value proposition in Mabu’s ability to improve treatment adherence, outcomes and data collection.

Healthcare systems also seek to benefit, as improved outcomes in patients will in turn reduce the need for unnecessary re-admissions, saving approximately $20,000 per patient. Similarly,  Mabu’s effect on reversing patient non-adherence to treatment programs could reduce the current $200B yearly cost to heath systems.

^{BY: BRETT JOHNSON, EDITOR-IN-CHIEF}

“Value-driven” vs. “volume-driven” was the theme of a discussion between top management of the country’s important healthcare institutions. Leaders of Mayo Clinic, United Healthcare, IBM and Medtronic addressed over 2,000 medical technology executives at the 10th Annual AdvaMed conference in Minneapolis, giving their outlook on the future of healthcare.

Panelists included Deborah DiSanzo, General Manager of IBM Watson Health, Omar Ishrak, Chairman & CEO of Medtronic, Richard Migliori, MD Chief Medical Officer of UnitedHealth Group and John Noseworthy MD, President & CEO Mayo Clinic.  The event was moderated by Susan Dentzer, CEO of the Network for Excellence in Health Innovation.

The discussion offered a generally encouraging view that the healthcare sector has been strengthened by the power of partnerships and collaboration, along with the value of big data. Specifically, they highlighted big data’s capacity to lower costs by avoiding adverse events and delivering better and more defined outcomes, ushering in a level of accountability to the healthcare system that was not previously possible. It was their consensus that this will drive forward business models that reward for outcomes versus activity.

Big Data of Big Importance in Healthcare

The arrival of big data is increasing the quality of patient care. For the first time, organizations can crunch data and analyze millions of records of healthcare treatments and outcomes. Panelists cited the collaboration of Mayo Clinic and Optum Labs (the health IT unit of UnitedHealth), to launch a collaborative research and development facility where over 100 million clinical and claims records dating back more than 15 years will be shared for the aim of improving patient care.

According to Mayo Clinic CEO John Noseworthy MD, “This will leverage what we believe to be the largest combined source of clinical and claims information, providing a more comprehensive picture of patient diagnoses, progression of diseases, comparative treatments and outcomes.”

Artificial Intelligence in Healthcare

This combination of data with the power of advanced computing power makes artificial intelligence possible, changing the future of health and medicine by using empirical data to prescribe the most effective treatment regime.

One such project, IBM Watson Health, symbolizes a new era of cognitive healthcare. The company is collaborating with the other major payors, providers and manufacturers to build systems that better understand issues in healthcare delivery.

Watson, which has already demonstrated its ability to beat the Grandmaster chess champion, is now on a path to use its extraordinary computing power to provide diagnoses for treatment as extraordinary as the most talented and experienced physician.

The notion that machines may replace physicians was also notes, perhaps to address the shortage of healthcare professionals that is predicted in future. However, their discussion mostly centered on the dramatic impact of this advance in computing power on the healthcare ecosystem through its ability to demonstrate and document results.

Marriage of Technology and Humanity is Just Beginning

According to IBM Watson GM Deborah DiSanzo we are at a similar juncture as the Internet in the 1990s. This is merely the beginning in terms of technology’s impact on healthcare. DiSanzo described it as a “marriage of technology and humanity”.

In summary, the panelists highlighted the great progress made over the past five years, and noted the need for the health sector to work together.  Silos need to break down. Success will require a new ecosystem and a culture of partnerships is critical for additional progress. According to Noseworthy, this is a conversation that was not possible 10 years ago.

www.onemednews.com

These recent validation data show further proof that ATB-346 can be effective even if administered
at a lower dosage. The frequency of taking it has also been proven to be effective at a once-a-day
rate.

ATB-346 is a Non-Steroidal Anti-Inflammatory Drug (NSAID); a Naproxen derivative that releases
hydrogen-sulfide. Its primary mechanism of action includes Cyclo oxygenase (COX) as inhibitor. Testing for the product has been made using dosages that range from 25 milligrams up to 1,000
milligrams. During the testing, inhibition was maintained for 24 hours, they also found that it can provide substantial inhibition for doses as low as 75 milligrams.

Development for ATB-346 has been started in the earlier part of the decade presenting potential
advantages for relief of inflammatory disorders without the common side effects. Unlike other
similar NSAIDs like Ibuprofen and Aspirin, ATB-346 is seen to be a potent drug with similar efficacy yet reduced the negative impacts on the gastrointestinal tract like bleedings and ulcers that are commonly caused by its counterparts. It was found out in various related studies on hydrogen-sulfide that the substance is a prospective gastrointestinal protective agent. Due to the hydrogen-sulfide releasing capacity of the drug, ATB-346 can protect the stomach from further ulcers and bleeding and even hasten the healing of pre-existing injuries.

As the development and testing of the product continues, Antibe Therapeutics is set to release
additional validation results as they advance.

Procter & Gamble have been reported to look at other similar technologies but it is WaferGen’s product that stood out for them and got chosen. This partnership can be implied as a further proof of SmartChip MyDesign’s superiority as a technological product. Among its key advantages that made it stand out above the other similar technology on Procter & Gamble’s considerations list is its user-friendly and easy to configure interface. This technology also has the convenient feature of efficient presentation of its analysis in the customers’ own laboratories.

In a statement made by the President and CEO of Wafergen Biosystems Ivan Trifunovich, he expressed their pride about the partnership and further promoted the benefits that their product can provide to Procter & Gamble.  As mentioned on a press release published on their website, WaferGen enumerated qualities such as “best-in-class flexibility, high levels of sensitivity without the need for pre-amplification and a very low cost per reaction” to be top factors that makes SmartChip one of the finest quantitative PCR systems in the market today.

In an earlier announcement, Wafergen has informed the public regarding the success of its proof-of-concept undertaking regarding Single Cell analysis with the use of the SmartChip technology. By 2^nd quarter of 2015, Wafergen is set to offer Early Access program in line with this proof-of-concept study.

CBMG is a world-renowned company that develops medicines and treatment for degenerative diseases and cancers. Hunstworth Health is an international organization for healthcare marketing and communications who is best in the industry that can profile and recognize the most significant key opinion leaders to collaborate with CBMG for the rest of the KOA treatment clinical trials for Rejoin.

The Phase IIb of the research trial was executed by a prominent teaching hospital in China, namely the Shanghai Renji hospital. The trials involved enrollment of 53 patients with KOA who were given randomized, single-blind treatment.

The final patient for the Phase IIb of the clinical trials was given treatment by the last quarter of 2014. The company headed by the Chief Executive officer William Cao, released official validation data for the Phase IIb clinical trial on the latter part of March 2015 confirming previous claims gathered up from Phase Ia, giving the company much optimism that the treatment will create a positive outcome for the benefit of millions of KOA patients from China.

Capnia has been known as a leading company that develops non-invasive treatment and diagnosis of various diseases and medical conditions. Clinvest is a top clinical research company, with a strong background in the treatment of headaches, which makes the team-up a certain success. In accordance with the MOU, Clinvest will perform testing on up to 50 patients of suffering from episodic cluster headaches of the effects of Capnia’s non-inhaled nasal CO2.

CEO of Clinvest and founder of the Headache Care Center Dr. Roger K. Cady will be spearheading this research.  According to a press release, Cady was said to have expressed his delight regarding the said venture. In this said press release, Capnia’s CEO Anish Bhatnagar has also spoken up about his anticipation to start working together with the headache treatment pioneer Dr. Cady.

In this collaboration, Capnia will be providing their proprietary nasal CO2 product to be tested on the recipients, as well as support for logistics and finances. Clinvest, headed by Dr. Cady, will carry out the investigations on the clinical efficacy of Capnia’s technology in the treatment of cluster headaches, performing an investigator-sponsored clinical research.

Cluster headache is a medical condition, distinguished by a symptomatic chronic and severe pain on one side of the head; duration is each painful attack is from 15 minutes that can last for up to 3 hours at a time. These episodes may occur as frequent as a few times a day over a course of several months before they subside. Some cases have patients suffering from unremitting, lingering pain. Approximately 0.2 % of the population suffers from cluster headaches.

AEOL 10150 is a drug used for idiopathic pulmonary fibrosis. It comes in the form of a universal catalytic antioxidant used for the treatment of patients with the rare IPF condition. This dreadful disease affects only a few people in the country, which gives the patients very few treatment options since drugs for this disease have not been mass produced.

Aside from treatment of IPF, the drug has been observed to show beneficial effects for people who are involved with high doses of radiation, as with those being used in cancer treatment. To date, there have already been two human clinical studies to support this positive claim by Aeolus Pharma.

The research being conducted by Aeolus is under the supervision of the US Department of Health and Human Services, funded through the Biomedical Advanced Research and Development Authority (BARDA). The drug is seen to be a very potent cure for cancer patients that have been receiving radiation therapy and those who have delayed effects and pulmonary manifestations of acute radiation exposure or Lung-ARS (acute radiation syndrome).

In line with the orphan drug designation from FDA, the sponsor of the drug’s research program is granted an exclusive seven-year marketing privilege, federal grants, tax credits and clinical protocol aid from the FDA.